Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113270 - METHOD OF TREATING NEUTROPHILIC CONDITIONS

Publication Number WO/2020/113270
Publication Date 11.06.2020
International Application No. PCT/AU2019/051325
International Filing Date 04.12.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 17/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
A61P 17/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
10Anti-acne agents
A61P 37/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 17/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
A61P 17/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
10Anti-acne agents
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C07K 16/2866
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2866against receptors for cytokines, lymphokines, interferons
C07K 2317/515
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
515Complete light chain, i.e. VL + CL
Applicants
  • CSL INNOVATION PTY LTD [AU]/[AU]
Inventors
  • INGUANTI, Karen Lisa
  • AIREY, Jolanta
  • SIDHU, Jagdev
  • TORTORICI, Michael
  • YURASZECK, Theresa
Agents
  • FB RICE PTY LTD
Priority Data
62/774,97404.12.2018US
62/885,37312.08.2019US
62/897,48709.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD OF TREATING NEUTROPHILIC CONDITIONS
(FR) MÉTHODE DE TRAITEMENT D'AFFECTIONS NEUTROPHILES
Abstract
(EN)
The present disclosure relates to a method for reducing circulating neutrophils in a subject without causing sustained grade 3 or grade 4 neutropenia. The present disclosure also relates to methods for treating neutrophilic conditions with an antibody that inhibit G-CSF signalling. In particular, the present disclosure relates to methods of 5 treating neutrophilic dermatoses, such as hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP).
(FR)
La présente invention concerne un procédé permettant de réduire des neutrophiles circulants chez un sujet sans provoquer de neutropénie de grade 3 ou de grade 4. La présente invention concerne également des méthodes de traitement d'affections neutrophiles à l'aide d'un anticorps inhibant la signalisation de G-CSF. En particulier, la présente invention concerne des méthodes de traitement de dermatoses neutrophiles, telles que l'hidradenitis suppurativa (HS) et la pustulose palmoplantaire (PPP).
Latest bibliographic data on file with the International Bureau